E. Birmingham

FluAlert: a qualitative evaluation of providers' desired characteristics and concerns regarding computerized influenza vaccination alerts.

M. Stockwell, D. Vawdrey, R. Kukafka, 2011, Preventive medicine.

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB

R. Hoetelmans, N. Bakare, E. Birmingham, 2022, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials

J. Polli, V. Vannappagari, H. Crauwels, 2021, HIV medicine.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

H. Stellbrink, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea

T. Shim, K. Davis, N. Bakare, 2023, BMC Infectious Diseases.

Bedaquiline for multidrug-resistant TB in paediatric patients

N. Lounis, N. Bakare, E. Birmingham, 2021, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

K. Davis, S. Omar, N. Bakare, 2022, BMC Infectious Diseases.

Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.

H. Crauwels, P. Patel, E. Birmingham, 2023, The Journal of infectious diseases.